Pioglitazone, a thiazolidinedione class of drugs, controls the high blood sugar in type-2 diabetic patients. Pioglitazone used as a single or combination therapy with metformin and has provided better outcomes when adopted with diet and exercise in type-2 diabetes. Despite the health benefits, pioglitazone’s long-term use is associated with weight gain, respiratory tract infections, bone fractures, numbness, blurred vision, etc.
Due to these adverse effects, physicians have shifted their focus from pioglitazone to other effective and safe alternatives. To shed more light on pioglitazone’s clinical utility, Docplexus in association with the Research Society For Study Of Diabetes In India, has arranged an exclusive Indian Diabetes League Session on the topic Goodbye to Pioglitazone: Yes / No on 6th November 2020 from 7 pm. Stay tuned to get more insights!
